Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation

NACompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

September 26, 2024

Study Completion Date

September 28, 2024

Conditions
Liver CancerRadiofrequency AblationEsketamineDexmedetomidine
Interventions
DRUG

Dexmedetomidine-esketamine combination

Dexmedetomidine-esketamine mixture will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.

DRUG

Remifentanil

Remifentanil will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.

DRUG

Oxycodone

Oxycodone will be injected intravenously 10-15 min before puncture.

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER